SCHEMBL25753501

SCHEMBL25753501

Cc1nc2cc(C(=O)NC(C)(C)C)ccc2s1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.66
RAB9A P51151 7/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
TRPV1 Q8NER1 1/20 0.60
ACKR3 P25106 1/20 0.52
CHRNA7 P36544 1/20 0.50
HDAC6 Q9UBN7 2/20 0.49
HDAC3 O15379 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 2/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
CASP3 P42574 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25766322 0.90 NPC1 (0.64) NPC1RAB9ASMN1; SMN2TRPV1ACKR3
SCHEMBL19058585 0.84 NPC1 (0.71) NPC1RAB9ASMN1; SMN2TRPV1CHRNA7
SCHEMBL24052027 0.84 RAB9A (0.71) NPC1RAB9ASMN1; SMN2TRPV1CHRNA7
SCHEMBL25754145 0.80 RAB9A (0.66) NPC1RAB9ASMN1; SMN2TRPV1CHRNA7
SCHEMBL1105986 0.80 NPC1 (1.00) NPC1RAB9ASMN1; SMN2TRPV1CHRNA7
SCHEMBL4988297 0.79 TRPV1 (0.88) NPC1RAB9ASMN1; SMN2TRPV1HDAC6
SCHEMBL20481983 0.79 NPC1 (0.78) NPC1RAB9ASMN1; SMN2TRPV1ALDH1A1
SCHEMBL2970236 0.78 NPC1 (0.71) NPC1RAB9ASMN1; SMN2TRPV1CHRNA7
SCHEMBL31120903 0.78 NPC1 (0.71) NPC1RAB9ASMN1; SMN2TRPV1CHRNA7
SCHEMBL24052275 0.77 NPC1 (0.76) NPC1RAB9ASMN1; SMN2TRPV1CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240026358-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2024-01-25 US disclosed
US-20230203484-A1 DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203087-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF RNGTT, NSUN2, ALKBH1 NPC1 4128/4885RAB9A 4490/4885SMN1; SMN2 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.